CARsgen Therapeutics Launches Investigational Trial for CD38 CAR-T Therapy

CARsgen Therapeutics Launches Investigator-Initiated Trial for KJ-C2320



On January 20, 2025, CARsgen Therapeutics Holdings Limited announced a significant milestone in cancer treatment. The company, known for its innovative CAR T-cell therapies, reported that it has successfully administered the first dose of KJ-C2320, an advanced allogeneic CAR T-cell therapy targeting CD38, to a patient participating in an investigator-initiated trial (IIT). This trial is taking place in China and aims to evaluate the efficacy of KJ-C2320 in treating patients suffering from relapsed or refractory acute myeloid leukemia (R/R AML).

About KJ-C2320 and the THANK-uCAR® Platform


KJ-C2320 represents a breakthrough in the fight against hematologic malignancies. It has been developed using CARsgen's proprietary THANK-uCAR® platform, which enables the generation of allogeneic CAR-T cells with enhanced expansion and persistence.

Understanding the intricacies of allogeneic T-cell therapy is essential. Typically, there are two significant challenges: graft-versus-host disease (GvHD) and host versus graft response (HvGR). To overcome these challenges, CARsgen employs a unique strategy that involves disrupting specific genomic loci associated with T-cell receptors (TCR) and beta-2 microglobulin (B2M). This disruption minimizes the expression of these components, protecting the CAR T-cells from patient immune reactions.

However, one of the persistent threats in this therapy model is the attack from natural killer (NK) cells, which can identify and eliminate T cells lacking human leukocyte antigen class I (HLA-I) expression. To combat this, CARsgen has engineered TCR-/B2M-T cells with a CAR that specifically targets NKG2A, effectively hindering NK cell rejection of the CAR T cells. This innovative approach has shown promise in clinical studies, where therapies developed via the THANK-uCAR® platform achieved complete responses at levels comparable to traditional autologous CAR-T therapies.

CARsgen's Vision and Future


Founded with a mission to deliver cutting-edge treatments for patients battling cancer, CARsgen Therapeutics is an emerging biopharmaceutical leader. The company operates both in China and the U.S., focusing its research and development on revolutionary CAR T-cell therapies. CARsgen aims to create novel technologies and solutions that address the limitations of existing CAR T-cell therapies, enhancing safety, efficacy, and cost-effectiveness.

The company has established a comprehensive development framework that includes everything from target discovery to innovative CAR T-cell product development and large-scale clinical production, ensuring a holistic approach to tackling cancer treatment.

In summary, CARsgen Therapeutics' pioneering KJ-C2320 therapy could signify a new era of treatment for patients suffering from complex hematologic cancers. With the launch of this IIT, the biopharmaceutical field eagerly anticipates the findings that could reshape therapeutic interventions in oncology.

For more information on CARsgen and its developments, visit CARsgen Therapeutics.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.